Molecular dynamics simulations and novel drug discovery

References

• Ye W, Wang W, Jiang C, et al. Molecular dynamics simulations of amyloid fibrils: an in silico approach. Acta Biochim Biophys Sin (Shanghai). 2013;45:503–508.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen H, Bai H, et al. Molecular dynamics simulations on the oligomer-formation process of the GNNQQNY peptide from yeast prion protein Sup35. Biophy J. 2007;93:1484–1492.
   PubMed Web of Science ®Google Scholar
• Barducci A, Chelli R, Procacci P, et al. Misfolding pathways of the prion protein probed by molecular dynamics simulations. Biophy J. 2005;88:1334–1343.
   PubMed Web of Science ®Google Scholar
• Urbanc B, Betnel M, Cruz L, et al. Elucidation of amyloid β-protein oligomerization mechanisms: discrete molecular dynamics study. J Am Chem Soc. 2010;132:4266–4280.
   PubMed Web of Science ®Google Scholar
• Campos SRR, Machuqueiro M, Baptista AM. Constant-pH molecular dynamics simulations reveal a β-rich form of the human prion protein. J Phys Chem B. 2010;114:12692–12700.
   PubMed Web of Science ®Google Scholar
• Chen W, Kamp MW, Daggett V. Structural and dynamic properties of the human prion protein. Biophys J. 2014;106:1152–1163.
   PubMed Web of Science ®Google Scholar
• Santini S, Derreumaux P. Helix H1 of the prion protein is rather stable against environmental perturbations: molecular dynamics of mutation and deletion variants of PrP (90–231). Cell Mol Life Sci. 2014;61:951–960.
   Google Scholar
• DeMarco ML, Daggett V. From conversion to aggregation: protofibril formation of the prion protein. Proc Natl Acad Sci USA. 2004;101:2293.
   PubMed Web of Science ®Google Scholar
• Barducci A, Chelli R, Procacci P, et al. Metadynamics simulation of prion protein: β-structure stability and the early stages of misfolding. J Am Chem Soc. 2006;128:2705–2710.
   PubMed Web of Science ®Google Scholar
• Benetti F, Biarnés X, Attanasio F, et al. Structural determinants in prion protein folding and stability. J Mol Biol. 2014;426:3796–3810.
   PubMed Web of Science ®Google Scholar
• Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Mol Biol. 2002;9:646–652.
   Web of Science ®Google Scholar
• Moore DJ, West AB, Dawson VL, et al. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 2005;28:57–87.
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3:935–949.
   PubMed Web of Science ®Google Scholar
• McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Boil. 2007;11:494–502.
   PubMed Web of Science ®Google Scholar
• Cheng T, Li Q, Zhou Z, et al. Structure-based virtual screening for drug discovery: a problem-centric review. Aaps J. 2012;14:133–141.
   PubMed Web of Science ®Google Scholar
• Rastelli G, Rio AD, Degliesposti G, et al. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem. 2010;31:797–810.
   PubMed Web of Science ®Google Scholar
• Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med Res Rev. 2006;26:531–568.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shen Y, Liu H, et al. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase. J Chem Inf Model. 2011;51:3235–3246.
   PubMed Web of Science ®Google Scholar
• Xue W, Pan D, Yang Y, et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antivir Res. 2012;93:126–137.
   PubMed Web of Science ®Google Scholar
• Zheng G, Xue W, Wang P, et al. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study. Sci Rep-UK. 2016;6:26883.
   PubMed Web of Science ®Google Scholar
• Haq FU, Abro A, Raza S, et al. Molecular dynamics simulation studies of novel β-lactamase inhibitor. J Mol Graph Model. 2017;74:143–152.
   PubMed Web of Science ®Google Scholar
• Haile JM. Molecular dynamics simulation. New York: Wiley; 1992.
   Google Scholar
• Spellings M, Marson RL, Anderson JA, et al. GPU accelerated Discrete Element Method (DEM) molecular dynamics for conservative, faceted particle simulations. J Comput Phys. 2017;334:460–467.
   Web of Science ®Google Scholar
• Pronk S, Páll S, Schulz R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29:845–854.
   PubMed Web of Science ®Google Scholar
• Adcock SA, McCammon JA. Molecular dynamics: survey of methods for simulating the activity of proteins. Chem Rev. 2006;106:1589–1615.
   PubMed Web of Science ®Google Scholar
• Klepeis JL, Lindorff-Larsen K, Dror RO, et al. Long-timescale molecular dynamics simulations of protein structure and function. Curr Opin Struc Biol. 2009;19:120–127.
   PubMed Web of Science ®Google Scholar
• Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781–1802.
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333–366.
   PubMed Web of Science ®Google Scholar
• Gsponer J, Haberthür U, Caflisch A. The role of side-chain interactions in the early steps of aggregation: molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. Proc Natl Acad Sci USA. 2003;100:5154–5159.
   PubMed Web of Science ®Google Scholar
• Lemkul JA, Bevan DR. Assessing the stability of Alzheimer’s amyloid protofibrils using molecular dynamics. J Phys Chem B. 2010;114:1652–1660.
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188–1203.
   PubMed Web of Science ®Google Scholar
• Levine H. Thioflavine T interaction with synthetic Alzheimer’s disease β‐amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404–410.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VMY, et al. α-Synuclein in lewy bodies. Nature. 1997;388:839–840.
   PubMed Web of Science ®Google Scholar
• Cooper GJ, Willis AC, Clark A, et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628–8632.
   PubMed Web of Science ®Google Scholar
• Hsich G, Kenney K, Gibbs CJ Jr, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. New Engl J Med. 1996;335:924–930.
   PubMed Web of Science ®Google Scholar
• Boellaard JW, Schlote W, Tateishi J. Neuronal autophagy in experimental Creutzfeldt-Jakob’s disease. Acta Neuropathol. 1989;78:410–418.
   PubMed Web of Science ®Google Scholar
• Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68:1718–1725.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766.
   PubMed Web of Science ®Google Scholar
• Gessel MM, Bernstein S, Kemper M, et al. Familial Alzheimer’s disease mutations differentially alter amyloid Β-protein oligomerization. ACS Chem Neurosci. 2012;3:909–918.
   PubMed Web of Science ®Google Scholar
• Nasica-Labouze J, Nguyen PH, Sterpone F, et al. Amyloid Β protein and Alzheimer’s disease: when computer simulations complement experimental studies. Chem Rev. 2015;115:3518–3563.
   PubMed Web of Science ®Google Scholar
• Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid Β-protein oligomerization. J Biol Chem. 2003;278:34882–34889.
   PubMed Web of Science ®Google Scholar
• CôTé S, Laghaei R, Derreumaux P, et al. Distinct dimerization for various alloforms of the amyloid-beta protein: aβ1–40, Aβ1–42, and Aβ1–40 (D23n). J Phys Chem B. 2012;116:4043–4055.
   PubMed Web of Science ®Google Scholar
• Lin Y-S, Pande VS. Effects of familial mutations on the monomer structure of Aβ 42. Biophys J. 2012;103:47–49.
   Web of Science ®Google Scholar
• Lin Y-S, Bowman GR, Beauchamp KA, et al. Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer. Biophys J. 2012;102:315–324.
   PubMed Web of Science ®Google Scholar
• Baumketner A, Krone MG, Shea J-E. Role of the familial Dutch mutation E22q in the folding and aggregation of the 15–28 fragment of the Alzheimer amyloid-Β protein. Proc Natl Acad Sci USA. 2008;105:6027–6032.
   PubMed Web of Science ®Google Scholar
• Huet A, Derreumaux P. Impact of the mutation A21g (Flemish Variant) on Alzheimer’s Β-amyloid dimers by molecular dynamics simulations. Biophys J. 2006;91:3829–3840.
   PubMed Web of Science ®Google Scholar
• Awasthi M, Singh S, Pandey VP, et al. Modulation in the conformational and stability attributes of the Alzheimer’s disease associated amyloid-beta mutants and their favorable stabilization by curcumin: molecular dynamics simulation analysis. J Biomol Struct Dyn. 2017;1–16.
   Google Scholar
• Benilova I, Gallardo R, Ungureanu AA, et al. The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J Biol Chem. 2014;289:30977–30989.
   PubMed Web of Science ®Google Scholar
• Das P, Murray B, Belfort G. Alzheimer’s protective A2T mutation changes the conformational landscape of the Aβ1-42 monomer differently than does the A2V mutation. Biophys J. 2015;108:738–747.
   PubMed Web of Science ®Google Scholar
• Zheng X, Liu D, Roychaudhuri R, et al. Amyloid β-protein assembly: differential effects of the protective A2T mutation and the recessive A2V familial Alzheimer’s disease mutation. ACS Chem Neurosci. 2015;6:1732–1740.
   PubMed Web of Science ®Google Scholar
• Nguyen PH, Sterpone F, Pouplana R, et al. Dimerization mechanism of Alzheimer Aβ40 peptides: the high content of intrapeptide-stabilized conformations in A2V and A2T heterozygous dimers retards amyloid fibril formation. J Phys Chem B. 2016;120:12111.
   PubMed Web of Science ®Google Scholar
• Viet MH, Nguyen PH, Derreumaux P, et al. Effect of the English familial disease mutation (H6r) on the monomers and dimers of Aβ40 and Aβ42. ACS Chem Neurosci. 2014;5:646–657.
   PubMed Web of Science ®Google Scholar
• Xu L, Chen Y, Wang X. Dual effects of familial Alzheimer’s disease mutations (D7h, D7n, and H6r) on amyloid Β peptide: correlation dynamics and zinc binding. Proteins. 2014;82:3286–3297.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the Α-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047.
   PubMed Web of Science ®Google Scholar
• Zarranz JJ, Alegre J, Gómez‐Esteban JC, et al. The new mutation, E46k, of Α‐synuclein causes Parkinson and lewy body dementia. Ann Neurol. 2004;55:164–173.
   PubMed Web of Science ®Google Scholar
• Lesage S, Anheim M, Letournel F, et al. G51d Α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome. Ann Neurol. 2013;73:459–471.
   PubMed Web of Science ®Google Scholar
• Xu L, Ma B, Nussinov R, et al. Familial mutations may switch conformational preferences in Α-synuclein fibrils. ACS Chem Neurosci. 2017;8:837–849.
   PubMed Web of Science ®Google Scholar
• Yu H, Han W, Ma W, et al. Transient Β-hairpin formation in Α-synuclein monomer revealed by coarse-grained molecular dynamics simulation. J Chem Phys. 2015;143:243142.
   PubMed Web of Science ®Google Scholar
• Wise-Scira O, Aloglu AK, Dunn A, et al. Structures and free energy landscapes of the wild-type and A30p mutant-type Α-synuclein proteins with dynamics. ACS Chem Neurosci. 2013;4:486–497.
   PubMed Web of Science ®Google Scholar
• Coskuner O, Wise-Scira O. Structures and free energy landscapes of the A53t mutant-type Α-synuclein protein and impact of A53t mutation on the structures of the wild-type Α-synuclein protein with dynamics. ACS Chem Neurosci. 2013;4:1101–1113.
   PubMed Web of Science ®Google Scholar
• Hazy E, Bokor M, Kalmar L, et al. Distinct hydration properties of wild-type and familial point mutant A53t of Α-synuclein associated with Parkinson’s disease. Biophys J. 2011;101:2260–2266.
   PubMed Web of Science ®Google Scholar
• Wise-Scira O, Dunn A, Aloglu AK, et al. Structures of the E46k mutant-type Α-synuclein protein and impact of E46k mutation on the structures of the Wild-Type Α-synuclein protein. ACS Chemi Neurosci. 2013;4:498–508.
   PubMed Web of Science ®Google Scholar
• Perlmutter JD, Braun AR, Sachs JN. Curvature dynamics of Α-synuclein familial Parkinson disease mutants molecular simulations of the micelle-and bilayer-bound forms. J Biol Chem. 2009;284:7177–7189.
   PubMed Web of Science ®Google Scholar
• Tsigelny IF, Sharikov Y, Kouznetsova VL, et al. Molecular determinants of Α-synuclein mutants’ oligomerization and membrane interactions. ACS Chem Neurosci. 2015;6:403–416.
   PubMed Web of Science ®Google Scholar
• Dlouhy SR, Hsiao K, Farlow MR, et al. Linkage of the Indiana Kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene. Nat Genet. 1992;1:64–67.
   PubMed Web of Science ®Google Scholar
• Wilesmith JW, Wells G, Cranwell MP, et al. Bovine spongiform encephalopathy: epidemiological studies. Vet Rec. 1988;123:638–644.
   PubMed Web of Science ®Google Scholar
• Pan K-M, Baldwin M, Nguyen J, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA. 1993;90:10962–10966.
   PubMed Web of Science ®Google Scholar
• Takada LT, Kim MO, Cleveland RW, et al. Genetic prion disease: experience of a rapidly progressive dementia center in the United States and a review of the literature. Am J Med Genet B. 2017;174:36–69.
   PubMed Web of Science ®Google Scholar
• Doss CGP, Rajith B, Rajasekaran R, et al. In silico analysis of prion protein mutants: a comparative study by molecular dynamics approach. Cell Biochem Biophys. 2013;67:1307–1318.
   PubMed Web of Science ®Google Scholar
• Borgohain G, Dan N, Paul S. Use of molecular dynamics simulation to explore structural facets of human prion protein with pathogenic mutations. Biophys Chem. 2016;213:32–39.
   PubMed Web of Science ®Google Scholar
• Ning L, Pan D, Zhang Y, et al. Effects of the pathogenic mutation A117V and the protective mutation H111S on the folding and aggregation of Prp106-126: insights from replica exchange molecular dynamics simulations. PloS One. 2015;10:e0125899.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang F, Zhang Y. Molecular dynamics studies on the NMR structures of rabbit prion protein wild type and mutants: surface electrostatic charge distributions. J Biomol Struct Dyn. 2015;33:1326–1335.
   PubMed Web of Science ®Google Scholar
• van der Kamp MW, Daggett V. Pathogenic mutations in the hydrophobic core of the human prion protein can promote structural instability and misfolding. J Mol Biol. 2010;404:732–748.
   PubMed Web of Science ®Google Scholar
• Chen W, Van Der Kamp MW, Daggett V. Diverse effects on the native Β-sheet of the human prion protein due to disease-associated mutations. Biochemistry. 2010;49:9874–9881.
   PubMed Web of Science ®Google Scholar
• Guo J, Ren H, Ning L, et al. Exploring structural and thermodynamic stabilities of human prion protein pathogenic mutants D202n, E211q and Q217r. J Struct Biol. 2012;178:225–232.
   PubMed Web of Science ®Google Scholar
• Guo J, Ning L, Ren H, et al. Influence of the pathogenic mutations T188k/R/a on the structural stability and misfolding of human prion protein: insight from molecular dynamics simulations. BBA- Gen Subjects. 2012;1820:116–123.
   PubMed Web of Science ®Google Scholar
• Kittner M. Folding and aggregation of amyloid peptides [ Doctoral dissertation]. Potsdam: Universität Potsdam, Diss.; 2011.
   Google Scholar
• Serpell LC. Alzheimer’s amyloid fibrils: structure and assembly. BBA-Mol Basis Dis. 2000;1502:16–30.
   PubMed Web of Science ®Google Scholar
• Grabenauer M, Wu C, Soto P, et al. Oligomers of the prion protein fragment 106−126 are likely assembled from Β-hairpins in solution, and methionine oxidation inhibits assembly without altering the peptide’s monomeric conformation. J Am Chem Soc. 2009;132:532–539.
   Web of Science ®Google Scholar
• Zhou S, Wang Q, Wang Y, et al. The folding mechanism and key metastable state identification of the Prp127–147 monomer studied by molecular dynamics simulations and Markov state model analysis. Phys Chem Chem Phys. 2017;19:11249–11259.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Chatterjee B, Basu S. A mechanistic insight into the amyloidogenic structure of hiapp peptide revealed from sequence analysis and molecular dynamics simulation. Biophys Chem. 2012;168:1–9.
   PubMed Web of Science ®Google Scholar
• Ning L, Wang Q, Zheng Y, et al. Effects of the A117V mutation on the folding and aggregation of palindromic sequences (PrP113-120) in prion: insights from replica exchange molecular dynamics simulations. Mol Biosyst. 2015;11:647–655.
   PubMed Web of Science ®Google Scholar
• Ning L, Guo J, Bai Q, et al. Structural diversity and initial oligomerization of PrP106–126 studied by replica-exchange and conventional molecular dynamics simulations. PloS One. 2014;9:e87266.
   PubMed Web of Science ®Google Scholar
• De Simone A, Pedone C, Vitagliano L. Structure, dynamics, and stability of assemblies of the human prion fragment SNQNNF. Biochem Bioph Res Co. 2008;366:800–806.
   PubMed Web of Science ®Google Scholar
• Xu W, Jiang P, Mu Y. Conformation preorganization: effects of S20G mutation on the structure of human islet amyloid polypeptide segment. J Phys Chem B. 2009;113:7308–7314.
   PubMed Web of Science ®Google Scholar
• Kundu S. Effects of different force fields on the structural character of Α synuclein Β-hairpin peptide (35-56) in aqueous environment. J Biomol Struct Dyn. 2017;1–16.
   Google Scholar
• Sugita Y, Okamoto Y. Replica-exchange molecular dynamics method for protein folding. Chem Phys Lett. 1999;314:141–151.
   Web of Science ®Google Scholar
• Kästner J. Umbrella sampling. WIRES Comput Mol Sci. 2011;1:932–942.
   Web of Science ®Google Scholar
• Laio A, Gervasio FL. Metadynamics: a method to simulate rare events and reconstruct the free energy in biophysics, chemistry and material science. Rep Prog Phys. 2008;71:126601.
   Web of Science ®Google Scholar
• Pande VS. An introduction to Markov state models and their application to long timescale molecular simulation. Stanford: Advances in Experimental Medicine and Biology; 2013.
   Google Scholar
• Freddolino PL, Harrison CB, Liu Y, et al. Challenges in protein folding simulations: timescale, representation, and analysis. Nat Phys. 2010;6:751.
   PubMed Web of Science ®Google Scholar
• Mo Y, Lu Y, Wei G, et al. Structural diversity of the soluble trimers of the human amylin (20–29) peptide revealed by molecular dynamics simulations. J Chem Phys. 2009;130:125101.
   PubMed Web of Science ®Google Scholar
• Nguyen PH, Derreumaux P. Conformational ensemble and polymorphism of the all-atom Alzheimer’s Aβ37–42 amyloid peptide oligomers. J Phys Chem B. 2013;117:5831–5840.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang Y, Ning L, et al. Stabilities and structures of islet amyloid polypeptide (IAPP22-28) oligomers: from dimer to 16-mer. BBA-Gen Subjects. 2014;1840:357–366.
   PubMed Web of Science ®Google Scholar
• Chua KP, Chew LY, Mu Y. Replica exchange molecular dynamics simulation of cross‐fibrillation of Iapp and Prp106‐126. Proteins. 2016;84:1134–1146.
   PubMed Web of Science ®Google Scholar
• Hu R, Zhang M, Chen H, et al. Cross-seeding interaction between Β-amyloid and human islet amyloid polypeptide. ACS Chem Neurosci. 2015;6:1759–1768.
   PubMed Web of Science ®Google Scholar
• Zhang M, Hu R, Liang G, et al. Structural and energetic insight into the cross-seeding amyloid assemblies of human Iapp and Rat Iapp. J Phys Chem B. 2014;118:7026–7036.
   PubMed Web of Science ®Google Scholar
• Baram M, Atsmon-Raz Y, Ma B, et al. Amylin–aβ oligomers at atomic resolution using molecular dynamics simulations: a link between Type 2 diabetes and Alzheimer’s disease. Phys Chem Chem Phys. 2016;18:2330–2338.
   PubMed Web of Science ®Google Scholar
• Jose JC, Chatterjee P, Sengupta N. Cross dimerization of amyloid-Β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study. PloS One. 2014;9:e106883.
   PubMed Web of Science ®Google Scholar
• William PE, Evelyn RS, Joan MJ, et al. Alzheimer’s disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry. 2000;39:6288–6295.
   PubMed Web of Science ®Google Scholar
• Nguyen PH, Mai SL, Stock G, et al. Monomer adds to preformed structured oligomers of Aβ-peptides by a two-stage dock–lock mechanism. Proc Natl Acad Sci USA. 2007;104:111.
   PubMed Web of Science ®Google Scholar
• Schor M, Vreede J, Bolhuis PG. Elucidating the locking mechanism of peptides onto growing amyloid fibrils through transition path sampling. Biophys J. 2012;103:1296–1304.
   PubMed Web of Science ®Google Scholar
• Meng X-Y, Zhang H-X, Mezei M, et al. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7:146–157.
   PubMed Web of Science ®Google Scholar
• Lee H, Mittal A, Patel K, et al. Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings. Bioorg Med Chem. 2014;22:167–177.
   PubMed Web of Science ®Google Scholar
• Hu X, Vujanac M, Southall N, et al. Inhibitors of the Yersinia protein tyrosine phosphatase through high throughput and virtual screening approaches. Bioorg Med Chem Lett. 2013;23:1056–1062.
   PubMed Web of Science ®Google Scholar
• Polgar T, Keseru GM. Integration of virtual and high throughput screening in lead discovery settings. Comb Chem High Throughput Screen. 2011;14:889–897.
   PubMed Web of Science ®Google Scholar
• Gong LL, Fang LH, Peng JH, et al. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors. J Biotechnol. 2010;145:295–303.
   PubMed Web of Science ®Google Scholar
• Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432:862–865.
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45:177–182.
   PubMed Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27:221–234.
   PubMed Web of Science ®Google Scholar
• Lyne PD. Structure-based virtual screening: an overview. Drug Discovery Today. 2002;7:1047–1055.
   PubMed Web of Science ®Google Scholar
• Sliwoski G, Kothiwale S, Meiler J, et al. Computational methods in drug discov. Pharmacol Rev. 2014;66:334–395.
   PubMed Web of Science ®Google Scholar
• Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24:417–422.
   PubMed Web of Science ®Google Scholar
• Cavasotto CN, Orry AJW. Ligand docking and structure-based virtual screening in drug discovery. Curr Top Med Chem. 2007;7:1006–1014.
   PubMed Web of Science ®Google Scholar
• Cross JB, Thompson DC, Rai BK, et al. Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. J Chem Inf Model. 2009;49:1455–1474.
   PubMed Web of Science ®Google Scholar
• Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: comparative data on docking algorithms. J Med Chem. 2004;47:558–565.
   PubMed Web of Science ®Google Scholar
• Schulz-Gasch T, Stahl M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model. 2003;9:47–57.
   PubMed Web of Science ®Google Scholar
• Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J Comput Aided Mol Des. 2002;16:151–166.
   PubMed Web of Science ®Google Scholar
• Zhou H-X. From induced fit to conformational selection: a continuum of binding mechanism controlled by the timescale of conformational transitions. Biophys J. 2010;98:L15–L7.
   PubMed Web of Science ®Google Scholar
• Wlodarski T, Zagrovic B. Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin. Proc Natl Acad Sci USA. 2009;106:19346–19351.
   PubMed Web of Science ®Google Scholar
• Hammes GG, Chang Y-C, Oas TG. Conformational selection or induced fit: a flux description of reaction mechanism. Proc Natl Acad Sci USA. 2009;106:13737–13741.
   PubMed Web of Science ®Google Scholar
• Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles i biomolecular recognition. Nat Chem Biol. 2009;5:789–796.
   PubMed Web of Science ®Google Scholar
• Antunes DA, Devaurs D, Kavraki LE. Understanding the challenges of protein flexibility in drug design. Expert Opin Drug Discov. 2015;10:1301–1313.
   PubMed Web of Science ®Google Scholar
• Fukunishi Y. Structural ensemble in computational drug screening. Expert Opin Drug Metab Toxicol. 2010;6:835–849.
   PubMed Web of Science ®Google Scholar
• Miao Y, Goldfeld DA, Von Moo E, et al. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Proc Natl Acad Sci USA. 2016;113:E5675–E5684.
   PubMed Web of Science ®Google Scholar
• Vass M, Schmidt E, Horti F, et al. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. Eur J Med Chem. 2014;77:38–46.
   PubMed Web of Science ®Google Scholar
• Wada M, Kanamori E, Nakamura H, et al. Selection of in silico drug screening results for G-protein-coupled receptors by using universal active probes. J Chem Inf Model. 2011;51:2398–2407.
   PubMed Web of Science ®Google Scholar
• Han M, Zhang JZH. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation. J Chem Inf Model. 2010;50:136–145.
   PubMed Web of Science ®Google Scholar
• Barakat KH, Huzil JT, Jordan KE, et al. A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. Mol Pharm. 2013;10:4572–4589.
   PubMed Web of Science ®Google Scholar
• Offutt TL, Swift RV, Amaro RE. Enhancing virtual screening performance of protein kinases with molecular dynamics simulations. J Chem Inf Model. 2016;56:1923–1935.
   PubMed Web of Science ®Google Scholar
• Spyrakis F, Benedetti P, Decherchi S, et al. A pipeline to enhance ligand virtual screening: integrating molecular dynamics and fingerprints for ligand and proteins. J Chem Inf Model. 2015;55:2256–2274.
   PubMed Web of Science ®Google Scholar
• Swift RV, Jusoh SA, Offutt TL, et al. Knowledge-based methods to train and optimize virtual screening ensembles. J Chem Inf Model. 2016;56:830–842.
   PubMed Web of Science ®Google Scholar
• Tian S, Sun H, Pan P, et al. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility. J Chem Inf Model. 2014;54:2664–2679.
   PubMed Web of Science ®Google Scholar
• Kong X, Pan P, Li D, et al. Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors. Phys Chem Chem Phys. 2015;17:6098–6113.
   PubMed Web of Science ®Google Scholar
• Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10:449–461.
   PubMed Web of Science ®Google Scholar
• Greenidge PA, Kramer C, Mozziconacci JC, et al. Improving docking results via reranking of ensembles of ligand poses in multiple X-ray protein conformations with MM-GBSA. J Chem Inf Model. 2014;54:2697–2717.
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Li Y, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods: I. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model. 2011;51:69–82.
   PubMed Web of Science ®Google Scholar
• Shen J, Tan C, Zhang Y, et al. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening. J Med Chem. 2010;53:5361–5365.
   PubMed Web of Science ®Google Scholar
• Ge H, Wang Y, Li C, et al. Molecular dynamics-based virtual screening: accelerating the drug discovery process by high-performance computing. J Chem Inf Model. 2013;53:2757–2764.
   PubMed Web of Science ®Google Scholar
• Cavalli A, Spitaleri A, Saladino G, et al. Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms. Acc Chem Res. 2015;48:277–285.
   PubMed Web of Science ®Google Scholar
• Gervasio FL, Laio A, Parrinello M. Flexible docking in solution using metadynamics. J Am Chem Soc. 2005;127:2600–2607.
   PubMed Web of Science ®Google Scholar
• Limongelli V, Bonomi M, Parrinello M. Funnel metadynamics as accurate binding free-energy method. Proc Natl Acad Sci U S A. 2013;110:6358–6363.
   PubMed Web of Science ®Google Scholar
• Freire E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today. 2008;13:869–874.
   PubMed Web of Science ®Google Scholar
• Olsson TS, Williams MA, Pitt WR, et al. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. J Mol Biol. 2008;384:1002–1017.
   PubMed Web of Science ®Google Scholar
• Bleicher KH, Bohm HJ, Muller K, et al. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2:369–378.
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng LJ, Huang YY, et al. Discovery of novel phosphodiesterase-2A inhibitors by structure-based virtual screening, structural optimization, and bioassay. J Chem Inf Model. 2017;57:355–364.
   PubMed Web of Science ®Google Scholar
• Hucke O, Coulombe R, Bonneau P, et al. Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency. J Med Chem. 2014;57:1932–1943.
   PubMed Web of Science ®Google Scholar
• Liu H, Yao X. Molecular basis of the interaction for an essential subunit PA−PB1 in influenza virus RNA polymerase: insights from molecular dynamics simulation and free energy calculation. Mol Pharm. 2010;7:75–85.
   PubMed Web of Science ®Google Scholar
• Sharon A, Balaraju T, Bal C. A catalytic 3D model development of HIV-integrase and drug resistance understanding by molecular dynamics simulation. Antiviral Res. 2011;90:A43–A44.
   Web of Science ®Google Scholar
• Hou T, W A M, Wang W. Evaluating the potency of HIV‐1 protease drugs to combat resistance. Proteins-Structure Funct Bioinform. 2008;71:1163–1174.
   PubMed Web of Science ®Google Scholar
• Jiao P, Xue W, Shen Y, et al. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study. Mol Biosyst. 2014;10:767–777.
   PubMed Web of Science ®Google Scholar
• Pan D, Sun H, Bai C, et al. Prediction of zanamivir efficiency over the possible 2009 Influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations. J Mol Model. 2011;17:2465–2473.
   PubMed Web of Science ®Google Scholar
• Pan D, Xue W, Zhang W, et al. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study. Biochimica et Biophysica Acta. 2012;1820:1526–1534.
   PubMed Web of Science ®Google Scholar
• Xue W, Jin X, Ning L, et al. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Modeling. 2013;53:210–222.
   PubMed Web of Science ®Google Scholar
• Xue W, Liu H, Yao X. Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: a molecular modeling perspective. J Comput Chem. 2012;33:527–536.
   PubMed Web of Science ®Google Scholar
• Pan P, Li L, Li Y, et al. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations. Antiviral Res. 2013;100:356–364.
   PubMed Web of Science ®Google Scholar
• Phanich J, Rungrotmongkol T, Kungwan N, et al. Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study. J Comput Aided Mol Des. 2016;30:917–926.
   PubMed Web of Science ®Google Scholar
• Woods CJ, Malaisree M, Pattarapongdilok N, et al. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus. Biochemistry. 2012;51:4364.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Gish RG. Future therapies for hepatitis C. Antivir Ther. 2006;11:397–408.
   PubMed Web of Science ®Google Scholar
• Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006;50:1013–1020.
   PubMed Web of Science ®Google Scholar
• Reed KE, Gorbalenya AE, Rice CM. The NS5A/NS5 proteins of viruses from three genera of the family flaviviridae are phosphorylated by associated serine/threonine kinases. J Virol. 1998;72:6199–6206.
   PubMed Web of Science ®Google Scholar
• Pan D, Niu Y, Xue W, et al. Computational study on the drug resistance mechanism of hepatitis C virus NS5B RNA-dependent RNA polymerase mutants to BMS-791325 by molecular dynamics simulation and binding free energy calculations. Chemometrics Intell Lab Syst. 2016;154:185–193.
   Web of Science ®Google Scholar
• Xue W, Qi J, Yang Y, et al. Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study. Mol Biosyst. 2012;8:2135–2144.
   PubMed Web of Science ®Google Scholar
• Qi C, Cheng X, Wei D, et al. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase. Interdiscip Sci Comput Life Sci. 2015;7:36–42.
   PubMed Web of Science ®Google Scholar
• Chen Q, Buolamwini JK, Smith JC, et al. Impact of resistance mutations on inhibitor binding to HIV-1 integrase. J Chem Inf Modeling. 2013;53:3297.
   PubMed Web of Science ®Google Scholar
• Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Boil. 2011;9:71.
   PubMed Web of Science ®Google Scholar
• Salomon-Ferrer R, Götz AW, Poole D, et al. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald J Chem Theor Comput. 2013;9:3878–3888.
   PubMed Web of Science ®Google Scholar
• Böde C, Kovács IA, Szalay MS, et al. Network analysis of protein dynamics. Febs Lett. 2007;581:2776–2782.
   PubMed Web of Science ®Google Scholar
• Marinari E, Parisi G. Simulated tempering: a new Monte Carlo scheme. Europhys Lett. 1992;19:451.
   Google Scholar
• Nguyen PH, Okamoto Y, Derreumaux P. Communication: simulated tempering with fast on-the-fly weight determination. J Chem Phys. 2013;138:061102.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ma J. Comparison of sampling efficiency between simulated tempering and replica exchange. J Chem Phys. 2008;129:134112.
   PubMed Web of Science ®Google Scholar
• Zhang T, Nguyen PH, Nasica-Labouze J, et al. Folding atomistic proteins in explicit solvent using simulated tempering. J Phys Chem B. 2015;119:6941–6951.
   PubMed Web of Science ®Google Scholar
• Man VH, Nguyen PH, Derreumaux P. High-Resolution Structures of the amyloid-β 1-42 dimers from the comparison of four atomistic force fields. J Phys Chem B. 2017;121:5977–5987.
   PubMed Web of Science ®Google Scholar
• Nguyen PH, Li MS, Derreumaux P. Effects of all-atom force fields on amyloid oligomerization: replica exchange molecular dynamics simulations of the Aβ 16–22 dimer and trimer. Phys Chem Chem Phys. 2011;13:9778–9788.
   PubMed Web of Science ®Google Scholar
• Freddolino PL, Harrison CB, Liu Y, et al. Challenges in protein folding simulations: timescale, representation, and analysis. Nature Phys. 2010;6:751–758.
   PubMed Web of Science ®Google Scholar
• Lane TJ, Shukla D, Beauchamp KA, et al. To milliseconds and beyond: challenges in the simulation of protein folding. Curr Opin Struc Boil. 2013;23:58–65.
   PubMed Web of Science ®Google Scholar
• Kim PM, Lu LJ, Xia Y, et al. Relating three-dimensional structures to protein networks provides evolutionary insights. Science. 2006;314:1938–1941.
   PubMed Web of Science ®Google Scholar